PT-141 15mg — Vial Spec, Reconstitution Math & COA

PT-141 15mg is a high-yield lyophilized peptide specification formatted for high-throughput preclinical research into central melanocortin receptor pathways. This technical reference details physical vial parameters, precise reconstitution calculations across standard diluent volumes, sub-aliquot planning, and analytical purity verification standards.

GMP-compliant U.S. facilities
ISO 17025 third-party COAs
100% domestic — no imports
Fast tracked domestic shipping
Shop research peptides

Quick answer

PT-141 15mg is a high-yield lyophilized peptide specification formatted for high-throughput preclinical research into central melanocortin receptor pathways. This technical reference details physical vial parameters, precise reconstitution calculations across standard diluent volumes, sub-aliquot planning, and analytical purity verification standards.

Reviewed by PX1 Research scientific team

Key takeaways

  • A 15mg vial of [PT-141](/research-peptides/pt-141) contains 15 milligrams of highly purified, vacuum-sealed lyophilized peptide powder (typically supplied as an acetate salt) formulated with a protective bulking agent matrix to maintain cake structure during cold-chain storage.
  • [PT-141](/research-peptides/pt-141), chemically identified as Bremelanotide (cyclo-[N-acetyl-L-norleucyl-L-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysine]), is a synthetic cyclic heptapeptide derivative of alpha-melanocyte-stimulating hormone (alpha-MSH).
  • Reconstituting a 15mg lyophilized peptide vial requires exact diluent calculations to establish predictable working concentrations for micro-pipetting.
  • Reconstituting a 15mg vial generates a substantial volume of working solution.

PT-141 15mg Vial Overview & Catalog Availability

A 15mg vial of PT-141 contains 15 milligrams of highly purified, vacuum-sealed lyophilized peptide powder (typically supplied as an acetate salt) formulated with a protective bulking agent matrix to maintain cake structure during cold-chain storage. This high-yield fill size is primarily specified by research institutions and laboratory teams conducting large-scale animal model trials or automated, multi-plate receptor binding assays where standard vial sizes require frequent container changes and reconstitution setups.

To maintain optimal stock turnover and minimize long-term liquid degradation in smaller assay configurations, PX1 Research maintains PT-141 10mg as our standard catalog fill size. Laboratories requiring custom 15mg fills or volume-scaled synthesis batches for extended trial series can access these through our wholesale inquiry portal. Researchers evaluating currently available unit sizes and related signaling compounds can review our complete catalog of all peptides.

Molecular Identity & Melanocortin Receptor Signaling Mechanism

PT-141, chemically identified as Bremelanotide (cyclo-[N-acetyl-L-norleucyl-L-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysine]), is a synthetic cyclic heptapeptide derivative of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical investigation demonstrates that PT-141 acts as a potent, non-selective melanocortin receptor agonist, displaying primary binding affinity for the melanocortin-3 receptor (MC3R) and melanocortin-4 receptor (MC4R) subtypes located centrally within the hypothalamus.

Unlike peripheral vasoactive research agents, PT-141 operates via central nervous system pathways. In vitro binding assays and rodent behavioral models indicate that activation of medial preoptic area (mPOA) MC4R circuits initiates downstream neurochemical cascades linked to sexual-health research pathways, including elevated dopamine release within the nucleus accumbens. Preclinical literature emphasizes its utility in probing central signaling circuits governing appetitive, motivational, and autonomic responses without acting directly on peripheral vascular smooth muscle nitric oxide pathways.

Reconstitution Math for 15mg Lyophilized Vials

Reconstituting a 15mg lyophilized peptide vial requires exact diluent calculations to establish predictable working concentrations for micro-pipetting. Laboratories typically utilize Bacteriostatic Water (0.9% benzyl alcohol) for multi-dose assay runs or sterile normal saline (0.9% NaCl) when evaluating sensitive cell-culture models. To verify custom volume calculations for various vial sizes, researchers can utilize our interactive reconstitution calculator.

The following volumetric calculations establish baseline concentration figures for a 15mg fill:

• 1.0 mL Diluent Addition: 15 mg / 1.0 mL = 15.0 mg/mL (15.0 mcg/uL). A 100 uL micro-pipette volume yields 1.5 mg (1500 mcg) of compound.

• 2.0 mL Diluent Addition: 15 mg / 2.0 mL = 7.5 mg/mL (7.5 mcg/uL). A 100 uL micro-pipette volume yields 0.75 mg (750 mcg) of compound.

• 3.0 mL Diluent Addition: 15 mg / 3.0 mL = 5.0 mg/mL (5.0 mcg/uL). A 100 uL micro-pipette volume yields 0.50 mg (500 mcg) of compound.

Standard laboratory protocol requires introducing the diluent slowly along the glass wall of the vial under partial vacuum. The container should be gently swirled until full dissolution occurs; mechanical shaking or high-speed vortexing must be avoided to prevent protein shear stress and aggregate formation.

Aliquot Planning and Serial Dilution Protocols

Reconstituting a 15mg vial generates a substantial volume of working solution. Because repeated septa punctures increase contamination risk and repeated freeze-thaw cycles compromise peptide bond integrity, sub-aliquoting is standard laboratory practice. Immediately after complete dissolution, the master solution should be divided into single-use, low-binding polypropylene micro-centrifuge tubes using barrier pipette tips.

For short-term testing schedules (under 14 days), reconstituted liquid aliquots prepared with bacteriostatic water should be preserved between 2°C and 8°C (36°F to 46°F) in a calibrated laboratory refrigerator. For long-term storage extending beyond two weeks, unpreserved or working aliquots must be flash-frozen at -20°C or -80°C. Frost-free freezers must be avoided, as their automatic thermal cycling induces micro-thawing that accelerates peptide hydrolysis.

Lot-Matched COA Verification & Quality Standards

Ensuring high experimental reproducibility across preclinical studies demands rigorous analytical verification. Every production lot of PT-141 synthesized for PX1 Research undergoes third-party verification at an independent ISO 17025 accredited laboratory prior to container filling and seal integrity verification. Laboratories can inspect batch-specific documentation by accessing our published Certificate of Analysis (COA) portal.

A complete COA for a PT-141 batch validates three primary chemical markers:

1. High-Performance Liquid Chromatography (HPLC): Confirms overall chemical purity equal to or exceeding 99.0%, ensuring the absence of truncated peptide sequences or synthesis side-products.

2. Mass Spectrometry (MS): Confirms exact molecular identity by verifying the theoretical monoisotopic mass (1024.2 Da) against the observed mass spectrum.

3. Endotoxin Testing (LAL Assay): Verifies bacterial endotoxin levels remain strictly below 0.1 EU/mg, preventing non-specific inflammatory responses in cellular assays or animal tissue models.

Comparative Analysis: Melanocortin & Related Neuropeptide Compounds

In preclinical neuro-endocrine research, PT-141 is frequently compared against other synthetic peptide ligands that target central melanocortin or pituitary receptor systems. While PT-141 demonstrates target affinity for MC3R and MC4R without inducing significant melanogenesis, its structural predecessor Melanotan II exhibits non-selective agonism across MC1R, MC3R, MC4R, and MC5R, stimulating dermal pigment pathways alongside central hypothalamic signaling.

When evaluating broader neuro-hormonal signaling cascades, investigators often cross-reference central melanocortin agonists with growth factor axis peptides such as CJC-1295 No DAC 5mg to differentiate melanocortinergic downstream signaling from pituitary somatotroph release pathways. Analyzing these distinct receptor binding profiles allows researchers to construct controlled experimental models within the broader framework of the PX1 Research library.

Selecting Fill Sizes: 10mg vs 15mg for Preclinical Design

Determining whether to utilize a 10mg or 15mg vial format depends on protocol scale, reagent throughput, and budget parameters. For single-assay microplates, small-cohort rodent screens, or initial binding assays, ordering a standard PT-141 10mg vial is typically optimal. Smaller fill sizes reduce liquid storage duration and minimize reagent loss due to degradation over extended testing windows.

Conversely, institutional laboratories executing multi-week animal screens or high-volume automated binding assays benefit from 15mg or larger custom fills due to improved per-milligram efficiency and batch consistency across large sample groups. Standardizing on a single larger fill batch reduces inter-vial variance across extensive experimental blocks.

Quality Assurance and Logistics at PX1 Research

PX1 Research maintains strict manufacturing and quality assurance standards for all catalog research peptides. Compounds are synthesized in cGMP-compliant facilities within the United States utilizing solid-phase peptide synthesis (SPPS), followed by preparative HPLC purification and sterile lyophilization into heavy-duty glass vials under negative pressure.

To preserve structural integrity during transit, orders are dispatched directly from our centralized logistics facilities located in California and Arizona. Same-day dispatch for orders confirmed Monday through Friday ensures rapid delivery, minimizing ambient thermal exposure prior to laboratory refrigeration.

Frequently Asked Questions

What is the primary molecular target of PT-141 in research models?

PT-141 (Bremelanotide) functions primarily as a central melanocortin receptor agonist, exhibiting selective high affinity for MC3R and MC4R subtypes within hypothalamic neural pathways.

Why might a laboratory specify a 15mg vial over a 10mg vial?

A 15mg fill size provides higher total yield per container, which is ideal for automated high-throughput screening or large animal model cohorts where single 10mg vials would require frequent reconstitution setups.

Does PX1 Research carry PT-141 15mg as a standard stock item?

PX1 Research carries PT-141 10mg as our primary stock item to optimize turnover and stability. However, 15mg and custom bulk formats are available for high-volume lab accounts upon request via our wholesale department.

How is concentration calculated when reconstituting a 15mg vial with 2 mL of diluent?

Dividing 15 mg by 2.0 mL of diluent yields a working concentration of 7.5 mg/mL (7.5 mcg/uL). A 100 uL volumetric pipette draw delivers 0.75 mg (750 mcg) of peptide.

What storage temperature is required for un-reconstituted lyophilized PT-141?

Lyophilized PT-141 powder should be stored long-term at -20°C in a desiccated environment protected from light. Under these conditions, structural stability is maintained for up to 24 months.

What endotoxin limit is verified on PX1 Research COAs?

All lot-matched COAs for PX1 Research peptides confirm bacterial endotoxin levels under 0.1 EU/mg, verified via LAL assay to prevent non-specific cell activation in vitro.

Can reconstituted PT-141 solution undergo repeated freeze-thaw cycles?

No. Repeated freeze-thaw cycles cause physical shear stress that leads to peptide chain cleavage and aggregation. Reconstituted stock should be partitioned into single-use aliquots before freezing.

How does PT-141 differ from Melanotan II in preclinical research?

While Melanotan II is a non-selective melanocortin agonist that activates MC1R (inducing melanogenesis) alongside central receptors, PT-141 displays target preference for central MC3R and MC4R pathways linked to neuro-endocrine signaling without stimulating dermal pigment pathways.

Related pages

All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.